Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Interstitial lung disease induced by alectinib (CH5424802/RO5424802).

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung adenocarcinoma was administered the selective anaplastic lymphoma kinase inhibitor, alectinib, as a third-line treatment in a Phase 1-2 study. On the 102nd day, chest computed tomography showed diffuse ground glass opacities. Laboratory data revealed high serum levels of KL-6, SP-D and lactate dehydrogenase without any clinical symptoms. There was no evidence of infection. Marked lymphocytosis was seen in bronchoalveolar lavage fluid analysis, and transbronchial lung biopsy showed mild thickening of alveolar septa and lymphocyte infiltration. Interstitial lung disease was judged to be related to alectinib based on improvements in imaging findings and serum biomarkers after discontinuation of alectinib. To our knowledge, this is the first reported case of alectinib-induced interstitial lung disease. Alectinib is a promising drug for ALK-rearranged non-small cell lung cancer. Clinical trials of this selective anaplastic lymphoma kinase inhibitor will facilitate the meticulous elucidation of its long-term safety profile.

          Related collections

          Author and article information

          Journal
          Jpn. J. Clin. Oncol.
          Japanese journal of clinical oncology
          Oxford University Press (OUP)
          1465-3621
          0368-2811
          Feb 2015
          : 45
          : 2
          Affiliations
          [1 ] Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama isatoshi0112@gmail.com.
          [2 ] Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama.
          [3 ] Department of Pathology, Kurashiki Central Hospital, Okayama.
          [4 ] Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
          Article
          hyu183
          10.1093/jjco/hyu183
          25398579

          Comments

          Comment on this article